Characterization of CMRF-56 antibody for isolation of blood dendritic cells for multiple myeloma immunotherapy  by Munster, D. et al.
339
IBRITUMOMAB TIUXETAN (ZEVALIN) IN THE CONDITIONING REGIMEN
FOR AUTOLOGOUS AND REDUCED-INTENSITY ALLOGENEIC STEM-
CELL TRANSPLANTATION (SCT) IN PATIENTS WITH CHEMO-REFRAC-
TORY NON-HODGKIN’S LYMPHOMA
Shimoni, A.1, Zwass, T.1, Oksman, Y.1, Hardan, I.1, Shem-Tov, N.,
Yerushalmi, R.1, Avigdor, A.1, Ben-Bassat, I.1, Nagler, A.1 Chaim
Sheba Medical Center, Tel-Hashomer, Israel.
High-dose chemotherapy and autologous SCT has an established
role in the treatment of patients (pts) with ﬁrst chemosensitive
relapse of aggressive lymphoma. However, autologous SCT has
only limited success when performed in refractory/progressive
stage, and the expected 1-year DFS in this setting is 20%.
Allogeneic SCT may offer some advantage by providing graft-
versus-lymphoma effect, but outcome is still poor in refractory
disease. This study was designed to explore the inclusion of Zevalin
in the conditioning regimens given prior to autologous and re-
duced-intensity allogeneic SCT (RIC) in pts with refractory lym-
phoma. The study included 24 pts, median age 56 years (range
35–66). Fifteen pts had autologous and 9 had RIC SCT (sibling-5,
unrelated-4). Histology was diffuse large cell (n 11), transformed
low-grade (n  9), mantle cell (n  3), and follicular lymphoma
(n  1). All pts had active lymphoma at SCT, either primary
refractory (n  9) or refractory relapse (n  15), and 14 had bulky
disease at SCT. The median number of prior therapies was 3
(range 1–6). Rituximab 250 mg/m2 followed by Zevalin 0.4
mCi/kg were given on day 14. Chemotherapy was started on day
6, and was standard BEAM prior to autologous SCT and the
combination of ﬂudarabine and intravenous busulfan (6.4 mg/kg)
or melphalan (140 mg/m2) prior to RIC. All pts engrafted. There
were no early infusion reactions associated with Zevalin. Fourteen
pts achieved CR , 4 achieved PR, and 6 are not evaluable (3 early
death, 3 too early after SCT). With a median follow-up of 8
months (range 1–16), 17 pts are alive and 7 have died with an
estimated 1-year survival of 62% (39–85), 68% after autologous
and 47% after allogeneic SCT (P  NS). The 1-year DFS is 46%
(18–73). So far, only 3 pts relapsed with a 1-year cumulative
incidence of only 24% (8–71). Three pts died of multi-organ
toxicities, 1 died of acute GVHD, and 2 of late infections. The
cumulative incidence of non-relapse mortality at day100 was 18%
(7–45), 13% after autologous and 30% after allogeneic SCT.
These rates are expected in heavily pretreated pts with refractory
lymphoma and there was no additional toxicity related to Zevalin.
In conclusion, the inclusion of Zevalin in the conditioning regi-
mens given prior to autologous and RIC allogeneic SCT may
reduce the risk of post SCT relapse and improve the poor outcome
of pts with refractory lymphoma given SCT with standard regi-
mens. This observation merits further study in larger comparative
studies.
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CHARACTERIZATION OF CMRF-56 ANTIBODY FOR ISOLATION OF
BLOOD DENDRITIC CELLS FOR MULTIPLE MYELOMA IMMUNOTHER-
APY
Munster, D.1, Rossetti, T.1, Prue, R.1, Vari, F.1, Hart, D.1 Mater
Medical Research Institute, Brisbane, Queensland, Australia.
The CMRF-56 antibody, which detects a blood dendritic cell
(BDC) marker, will be used for immunoselection of cells from
leukapheresis products for immunotherapy of multiple myeloma.
The development of the laboratory grade CMRF-56 to a product,
which can be used for clinical application, has involved careful
characterization of the antibody. We have discovered that the
immunoreactivity of this antibody is remarkably sensitive to both
the pH of the elution buffer and time of exposure. Exposure of
antibody to pH2.0 for greater than 10 minutes completely abol-
ishes activity after an initial rapid increase in potency, pH2.5
resulted in a gradual increase in antibody potency that peaks at
approximately 5 hours, whilst maximum potency is reached at 100
hours after exposure to pH3.0. As a result of this sensitivity to acid
exposure, the consistency between CMRF-56 batches could be
highly variable. To improve this, antibody elution conditions were
standardized by controlling the time of exposure of the antibody.
Immunoselection using CMRF-56 antibodies eluted at different
pH indicated that the pH2.5 elution resulted in CMRF-56 BDC
preparations of acceptable yield and purity while the pH 2.0 elu-
tion produced BDC preparations with unacceptably low purity due
to contaminating monocytes and B cells. We found that the degree
of CMRF-56 antibody aggregation correlates strongly with immu-
noreactivity, indicating the mechanism of antibody binding may be
enhanced by aggregation or dimerisation. It was also possible to
markedly increase the immunoreactivity of the puriﬁed monomeric
form of CMRF-56 by short-term exposure to acid. These studies
have resulted in the development of a bioprocess for production of
the murine biotinylated CMRF-56 antibody which is compatible
with large-scale synthesis required for clinical trials. The biopro-
cess incorporates components which remove contaminating DNA,
host cell proteins, virus and endotoxin.
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IMMUNE CONSOLIDATION AFTER STEM CELL TRANSPLANT FOR
CD20 NONHODGKIN’S LYMPHOMA USING MULTIPLE INFUSIONS OF
AUTOLOGOUS ACTIVATED T CELLS (ATC) WITH ANTI-CD3 x ANTI-
CD20 BISPECIFIC ANTIBODY (CD20Bi) TO IMPROVE GRAFT-VS-LYM-
PHOMA EFFECTS
Lum, L.G.1,2, Davol, P.1, Colvin, G.1,2, Rathore, R.1,2, Abedi, M.1,2,
Palushock, E.1, Olson, A.1, Tarro, T.1, Quesenberry, P.1,2 1. Roger
Williams Hospital, Providence, RI; 2. Boston University, Boston, MA.
Relapse after autologous stem cell transplant (SCT) for high risk
in remission, refractory or relapsed non-Hodgkin’s lymphoma
(NHL) patients remain unacceptably high. In order to augment the
anti-lymphoma effect and decrease relapsed rates, we combine the
cytotoxicity mediated by anti-CD3 activated autologous T cells
(ATC) armed with a anti-CD3 x anti-CD20 bispeciﬁc antibody
(CD20Bi) that redirects ATC to kill CD20 targets with SCT
after high dose chemotherapy (HDC). Arming with CD20Bi con-
verts each T cell into a cytotoxic T lymphocyte directed at CD20
targets. Our phase I trial tests whether multiple infusions of armed
ATC given after HDC consisting of cyclophosphamide, thiotepa,
and carboplatin (CTC) as a preparative regimen followed by SCT
are safe. Furthermore, we will evaluate whether such infusions will
provide an anti-lymphoma effect to improve overall survival and
disease free survival after SCT for NHL. Beginning day 4, the
patients receive immune consolidation consisting of 3 infusions of
CD20Bi-armed ATC per week for 3 weeks and then 1 infusion per
week for 6 additional weeks. Dose levels for the phase I trial are 5,
10, 15, and 20  109 cells/infusion with total armed ATC doses
equaling 75, 150, 225, and 300  109 CD20Bi-armed ATC. Pa-
tients receive daily subcutaneous IL-2 (300,000 IU/m2/day) begin-
ning within 24 hours of the ﬁrst infusion and ending on the day of
the last infusion. One patient has completed the ﬁrst dose level.
The ﬁrst patient was a 58 year old man with relapsed diffuse, large
B-cell lymphoma. He was primed with G-CSF, leukapheresed for
CD34 enriched PBSC and lymphocytes. His CD34 enriched
PBSC were cryopreserved and his T cells were expanded with
anti-CD3 activation and IL-2. The infused armed ATC product
was 96% CD3, 44% CD4, 53% CD8, 81% CD4CD45/RO,
and 93% CD8CD45/RO. He received a SCT after CTC and
completed all 15 infusions at the ﬁrst dose-level (total of 75  109)
without any side-effects. He is 90 days after SCT and his restaging
is pending. The cytotoxicicity mediated by the patient’s ex vivo
expanded, armed ATC against the B9C cell line was considerably
higher than unarmed ATC. These early results suggest that large
numbers of armed autologous ATC can be infused after HDC and
SCT without major side effects. This strategy used in combination
with HDC and SCT may provide an unique opportunity to in-
crease the GVL effect without increasing toxicities after SCT for
hematologic malignancies.
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A COMPARISON OF MOLECULAR PROGNOSTIC TESTS IN MULTIPLE
MYELOMA
van den Berghe, J.1, Fesser, J.1, Wanda, H.1,2, Michael, V.1,2 1.
University of Saskatchewan, Saskatoon, SK, Canada; 2. Stem Cell
Transplant Program, Saskatchewan Cancer Agency, Saskatoon, SK,
Canada.
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